Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: magnesium stearate; crospovidone; lactose monohydrate; meglumine; colloidal anhydrous silica; sodium hydroxide; povidone - telmisartan is indicated for:,treatment of hypertension ,prevention of cardiovascular morbidity and mortality in patients 55 years or older with,coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic,attack or high risk diabetes with evidence of end organ damage.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; crospovidone; povidone; sodium hydroxide; meglumine; colloidal anhydrous silica; magnesium stearate - telmisartan is indicated for:,treatment of hypertension ,prevention of cardiovascular morbidity and mortality in patients 55 years or older with,coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic,attack or high risk diabetes with evidence of end organ damage.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - quetiapine fumarate, quantity: 172.704 mg (equivalent: quetiapine, qty 150 mg) - tablet, film coated - excipient ingredients: povidone; titanium dioxide; microcrystalline cellulose; lactose monohydrate; magnesium stearate; sodium starch glycollate type a; macrogol 400; iron oxide yellow; calcium hydrogen phosphate dihydrate; hypromellose - quetiapine is indicated for:,bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - quetiapine fumarate, quantity: 115.136 mg (equivalent: quetiapine, qty 100 mg) - tablet, film coated - excipient ingredients: macrogol 4000; calcium hydrogen phosphate dihydrate; magnesium stearate; titanium dioxide; microcrystalline cellulose; lactose monohydrate; hypromellose; povidone; sodium starch glycollate type a; iron oxide yellow - quetiapine is indicated for:,bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - quetiapine fumarate, quantity: 345.408 mg (equivalent: quetiapine, qty 300 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; titanium dioxide; hypromellose; macrogol 400; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; sodium starch glycollate type a; magnesium stearate; povidone - quetiapine is indicated for:,bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - quetiapine fumarate, quantity: 28.784 mg (equivalent: quetiapine, qty 25 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; hypromellose; magnesium stearate; titanium dioxide; calcium hydrogen phosphate dihydrate; sodium starch glycollate type a; povidone; iron oxide red; iron oxide yellow; lactose monohydrate; macrogol 400 - quetiapine is indicated for:,bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - quetiapine fumarate, quantity: 230.272 mg (equivalent: quetiapine, qty 200 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; titanium dioxide; calcium hydrogen phosphate dihydrate; macrogol 400; magnesium stearate; hypromellose; sodium starch glycollate type a; lactose monohydrate; povidone - quetiapine is indicated for:,bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - hydrochlorothiazide, quantity: 25 mg; olmesartan medoxomil, quantity: 40 mg - tablet - excipient ingredients: lactose monohydrate; microcrystalline cellulose; hyprolose; stearic acid; magnesium stearate; purified water; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red; macrogol 400 - olmesartan medoxomil and hydrochlorothiazide is indicated for:,treatment of hypertension.,treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olmesartan medoxomil, quantity: 40 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet - excipient ingredients: magnesium stearate; purified water; stearic acid; hyprolose; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red; macrogol 400 - olmesartan medoxomil and hydrochlorothiazide is indicated for:,treatment of hypertension.,treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - hydrochlorothiazide, quantity: 12.5 mg; olmesartan medoxomil, quantity: 20 mg - tablet - excipient ingredients: lactose monohydrate; stearic acid; purified water; hyprolose; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red; macrogol 400 - olmesartan medoxomil and hydrochlorothiazide is indicated for:,treatment of hypertension.,treatment should not be initiated with this fixed dose combination.